ALDEI.PA Deinove SA (EURONEXT) €0.0265 on 11 Feb 2026: Most-active stock with high volume

ALDEI.PA stock is trading as one of the most active small-caps on EURONEXT intraday on 11 Feb 2026, changing hands at €0.0265 with 13,014,939 shares traded so far. Volume is more than double the average, driven by speculative flows and microcap liquidity. Investors watching biotechnology names should note Deinove SA (ALDEI.PA) shows a wide intraday range, a thin market cap of about €1.13 million, and negative earnings per share of -0.24, which links any price move to news or funding updates.

Intraday price action for ALDEI.PA stock

ALDEI.PA stock opened at €0.0239 and is trading within a day low/high range of €0.0231 / €0.0321. One claim: the stock’s relative volume of 2.17x points to outsized intraday interest and fast intraday swings. Another claim: with a 50-day average price of €0.02315 and a 200-day average of €0.11427, the current price sits near short-term resistance and far below long-term averages, so momentum traders are controlling intraday moves.

Trading liquidity and volume drivers for ALDEI.PA stock

One claim: 13,014,939 shares traded versus an average volume of 5,992,347 shows high liquidity today, but market cap near €1,134,989 still leaves price vulnerable to large orders. Another claim: most volume appears driven by retail flows and positioning ahead of potential corporate updates or partner announcements, given Deinove’s partnerships with bioMrieux and Institut Pasteur.

Fundamentals and valuation context for ALDEI.PA stock

One claim: Deinove reports EPS of -0.24 and a negative PE, reflecting pre-revenue or early-stage biotech economics; price-to-sales is 3.09 and EV/sales is 9.85, indicating rich valuation relative to tiny revenues. Another claim: key ratios show a current ratio of 1.36 and cash per share of 0.1344, which gives limited runway and makes fundraising risk a primary valuation driver.

Sector backdrop and risks for ALDEI.PA stock

One claim: ALDEI.PA operates in Healthcare and Biotechnology, sectors where average PE sits near 35.01 and institutional activity is higher; Deinove’s microcap profile therefore faces greater volatility than sector leaders. Another claim: primary risks include clinical trial outcomes (DNV3837 Phase II), dilution from capital raises, and weak free cash flow; these are typical biotech liquidity and execution risks.

Technical and market-grade signals for ALDEI.PA stock

One claim: price momentum shows a 3-month gain of 11.81% but a 6-month loss of -83.82%, signalling short-term buying inside a longer-term downtrend. Another claim: technical averages (50-day €0.02315, 200-day €0.11427) put the stock below its long-term trend, so breakouts need sustained volume to be credible.

Meyka AI grade and analyst-style outlook for ALDEI.PA stock

One claim: Meyka AI rates ALDEI.PA with a score out of 100: 64.99 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Another claim: the score reflects small market cap, negative EPS, and partnership potential; grades are informational only and not investment advice.

Final Thoughts

Key takeaways: ALDEI.PA stock is one of the most-active microcaps on EURONEXT intraday on 11 Feb 2026, trading at €0.0265 with 13,014,939 shares traded and a relative volume of 2.17x. The move is volume-led, not earnings-led: EPS is -0.24, free cash flow is negative, and the enterprise value to sales is 9.85, so fundamentals lag price action. For traders, intraday liquidity and sharp bid-ask swings create short-term opportunity and execution risk. For investors, the main drivers remain clinical progress for DNV3837, partner milestones, and funding events. Meyka AI’s forecast model projects a 12-month base-case of €0.040 versus the current price of EUR 0.0265, implying an upside of 50.94%; forecasts are model-based projections and not guarantees. Monitor cash runway, trial updates, and any equity issuance; use tight risk controls given high volatility and microcap liquidity dynamics. For further company detail see the company site and EURONEXT listing Deinove and Euronext Deinove page. Meyka AI is an AI-powered market analysis platform offering real-time scoring and forecasts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.